TIMOTHY J. PELURA, Ph.D., Chairman, President & CEO
Dr. Pelura joined Immunome in September of 2009 as President and CEO. He is a serial life science entrepreneur with over 35 years of experience in the pharmaceutical, biotech and medical device industries and has been pivotal in the development of several new drugs spanning numerous therapeutic areas.
Previously, Dr. Pelura was founding President and CEO of Promedior, a product-focused biotech company developing novel therapeutics for the treatment of fibrotic disorders and diseases. In less than 3 years, he attracted $30MM in tier 1 venture capital, established the corporate strategy, built the management team and brought this nascent technology to the clinic. Prior to Promedior, Dr. Pelura served as Chief Scientific Officer for Kereos, responsible for all R&D activities for their oncology, cardiology, and molecular imaging programs. Prior to joining Kereos, he served as President and COO of Provasis Therapeutics, a developer of interventional neurosurgical devices and was successful in selling the company to the largest medical device company in the world with significant returns for the investors. Dr. Pelura held executive R&D positions at Neuron Therapeutics and Alliance Pharmaceutical Corp. At both companies he was pivotal in the development and commercialization of numerous innovative medical products. Earlier, Dr. Pelura worked in various capacities at KabiVitrum and Pharmacia where he was involved with parenteral nutrition, drug delivery, and lipid emulsion research and development. Dr. Pelura, an avid believer in the tremendous potential of the tri-state region, is pivotally involved in several non-profit, regional life science development initiatives. Dr. Pelura holds a Ph.D. in chemistry from Rutgers University.

SCOTT K. DESSAIN, M.D., Ph.D., FOUNDER AND CHIEF SCIENTIFIC OFFICER
Dr. Dessain is an Associate Professor at the Lankenau Institute for Medical Research, Wynnewood PA. He received M.D. and Ph.D. degrees from Yale University in 1994. He pursued post-graduate medical training in Internal Medicine at Brigham and Women's Hospital, followed by a fellowship in Medical Oncology at Dana Farber/Partners Cancer Care Boston, MA. His post-doctoral training was with Dr. Robert Weinberg at the Whitehead Institute in Cambridge, MA, at which time he devised novel techniques to efficiently clone native human antibodies. Following his fellowship, he spent 2 years as an instructor at the Massachusetts General Hospital in Boston, specializing in bone marrow transplantation and malignant hematology, and then joined the faculty of the Cardeza Foundation for Hematologic Research at the Thomas Jefferson University in Philadelphia, where he continued to optimize human antibody cloning methods and work in clinical bone marrow transplantation. He founded Immunome in 2006 and served as President and CSO until September of 2009 when Dr. Pelura joined the team. He has contributed to 23 published articles, a U.S. patent, and 5 patent applications. Dr. Dessain has received K08 and R01 research grants from the National Institute of Health. He is Board-Certified in Medical Oncology and practices in an outpatient clinic at the Lankenau Hospital in Wynnewood, PA.

GEORGE D. HOBBS, J.D., SVP CORP. DEVELOPMENT AND GENERAL COUNSEL
Mr. Hobbs has more than 20 years of experience in the life science industry. Before joining Immunome in 2009, George had a leadership role in the formation and management of a start-up company that advanced a novel cellular therapy from discovery to clinical testing. He was also a member of the senior management team for 13 years at Centocor, Inc. during the successful development of several products from academic in-license opportunities through FDA approvals; and a $4.9 billion merger with Johnson and Johnson. Mr. Hobbs has experience with a broad range of legal and business matters, especially those relating to the development and execution of intellectual property, licensing and business development strategies. He received a B.S. in biology from Haverford College and a J.D. from The Dickinson School of Law. He is a member of the Pennsylvania Bar and licensed to practice before the US Patent and Trademark Office.